An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade

• DOI: 10.1136/jitc-2023-008504
• Publication Date: 2024-08-14T06:35:19Z
• Authors: Cesare Di Nitto; Domenico Ravazza; Ettore Gilardoni; Thomas Look; Miaomiao Sun; Eleonora Prodi; Vlad Moisoiu; Christian Pellegrino; Markus G. Manz; Emanuele Puca; Michael Weller; Tobias Weiss; Dario Neri; Roberto De Luca
• Keywords: Cancer Immunotherapy

Anti-PD-1 antibodies have revolutionized cancer immunotherapy due to their ability induce long-lasting complete remissions in a proportion of patients. Current research efforts are attempting identify biomarkers and suitable combination partners predict or further improve the activity immune checkpoint inhibitors. Antibody-cytokine fusions class pharmaceuticals that showed potential boost anticancer properties other immunotherapies. Extradomain A-fibronectin (EDA-FN), which is expressed most solid hematological tumors but virtually undetectable healthy adult tissues, an attractive target for delivery cytokine at site disease.